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provided it is propeBackground: The International Maternal, Pediatric, and Adolescent Clinical Trials
P1060 trial demonstrated superior outcomes for HIV-infected children less than 3
years old initiating antiretroviral therapy (ART) with lopinavir/ritonavir compared to
nevirapine, but lopinavir/ritonavir is four-fold costlier.
Design/methods: We used the Cost-Effectiveness of Preventing AIDS Complications
(CEPAC)-Pediatric model, with published and P1060 data, to project outcomes under
three strategies: no ART; first-line nevirapine (with second-line lopinavir/ritonavir); and
first-line lopinavir/ritonavir (second-line nevirapine). The base-case examined South
African children initiating ART at age 12 months; sensitivity analyses varied all key
model parameters. Outcomes included life expectancy, lifetime costs, and incremental
cost-effectiveness ratios [ICERs; dollars/year of life saved ($/YLS)]. We considered
interventions with ICERs less than 1 per-capita gross domestic product (South Africa:
$7500)/YLS as ‘very cost-effective,’ interventions with ICERs below 3 gross domestic
product/YLS as ‘cost-effective,’ and interventions leading to longer life expectancy and
lower lifetime costs as ‘cost-saving’.
Results: Projected life expectancy was 2.8 years with no ART. Both ART regimens
markedly improved life expectancy and were very cost-effective, compared to no ART.
First-line lopinavir/ritonavir led to longer life expectancy (28.8 years) and lower lifetime
costs ($41350/person, from lower second-line costs) than first-line nevirapine (27.6
years, $44 030). First-line lopinavir/ritonavir remained cost-saving or very cost-effective
compared to first-line nevirapine unless: liquid lopinavir/ritonavir led to two-fold higher
virologic failure rates or 15-fold greater costs than in the base-case, or second-line ART
following first-line lopinavir/ritonavir was very ineffective. Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
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 1248 AIDS 2015, Vol 29 No 10Conclusions: On the basis of P1060 data, first-line lopinavir/ritonavir leads to longer
life expectancy and is cost-saving or very cost-effective compared to first-line
nevirapine. This supports WHO guidelines, but increasing access to pediatric ART is
critical regardless of the regimen used.
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Approximately 3 million children live with HIV/AIDS
worldwide, and nearly 260 000 infants are HIV-infected
each year [1]. HIV-infected children below 3 years of age
face high risks of AIDS and death without effective
antiretroviral therapy (ART) [2]. The majority of HIV-
infected children live in sub-Saharan Africa, where fewer
than one-third have access to ART and the optimal
sequence of available ART medications remains unknown
[3–5]. Most African programs offer two sequential ‘lines’
of pediatric ART: a ‘first-line’ regimen including
nevirapine [a non-nucleoside reverse transcriptase inhibi-
tor (NNRTI)], followed after virologic failure by a
‘second-line’ regimen containing lopinavir/ritonavir (a
protease inhibitor) [5]. Nevirapine is inexpensive, widely
available, and formulated in fixed-dose combinations [6,7].
The recent International Maternal, Pediatric, and Adoles-
cent Clinical Trial (IMPAACT) P1060 study, however,
demonstrated superior 72-week suppression of HIV when
children aged below 3 years initiated first-line lopinavir/
ritonavir compared to first-line nevirapine, regardless of
prior antiretroviral drug exposure to prevent mother-to-
child HIV transmission [8,9]. The WHO now recom-
mends lopinavir/ritonavir-based first-line ART for chil-
dren below 3 years old [10]. Liquid lopinavir/ritonavir is
needed for children too young to swallow pills; it has a
high alcohol content and has been reported to have very
poor palatability, relies on a cold chain to the point of
distribution, and is four-fold costlier than nevirapine
[6,7,11]. Incorporating these tradeoffs in efficacy, tolerance,
and cost, we projected the long-term clinical outcomes
and cost-effectiveness of first-line nevirapine and
lopinavir/ritonavir for HIV-infected children below
3 years of age.Methods
Analytic overview
We used the Cost-Effectiveness of Preventing AIDS
Complications (CEPAC)-Pediatric model to evaluate three
treatment strategies for HIV-infectedchildrenbelow3 yearsCopyright © 2015 Wolters Kluwer Hof age: no ART (comparator); first-line nevirapine,
followed by second-line lopinavir/ritonavir; and first-line
lopinavir/ritonavir, followed by second-line nevirapine
[12]. In our base-case analysis, we simulated HIV-infected
children presenting to care and initiating ARTat 12 months
of age in South Africa. In sensitivity analyses, we examined
the impact of age at presentation to care and ART initiation
(6–35 months), lower healthcare costs from Coˆte d’Ivoire,
and variations in all other clinical and economic parameters,
on the comparison of the first-line ART regimens. Model
outcomes included yearly survival and healthcare costs over
short and long-term time horizons, cohort life expectancy,
and average lifetime healthcare costs. We calculated an
incremental cost-effectiveness ratio (ICER) for each
strategy compared to its next less expensive alternative:
difference in lifetime costs divided by difference in life-years
($/YLS). Following WHO guidance, we considered
interventions with ICERs less than three-times per-capita
gross domestic product (GDP; South Africa: $7500, Coˆte
d’Ivoire: $1200)/YLS to be ‘cost-effective,’ those with
ICERs below 1GDP/YLS to be ‘very cost-effective,’ and
those leading to longer projected life expectancy and lower
lifetime costs to be ‘cost-saving’ [13,14].
CEPAC-Pediatric model
The CEPAC-Pediatric model is a microsimulation model
of pediatric HIV disease (Appendix, see also http://
web2.research.partners.org/cepac/model.html) [12]. At
the start of each simulation, HIV-infected children draw
from distributions of HIV RNA and CD4þ levels; the
model uses CD4þ percentage (CD4þ%) for childrenbelow
5 years old and absolute CD4þ cell count thereafter [15].
Current age and CD4þ% or CD4þ cell count in each
month determine the risks of disease progression,
including development of acute opportunistic infections
and death. Without effective ART, CD4þ% or CD4þ cell
count declines monthly. Children can initiate ART based
on a combination of observed criteria, including age,
CD4þ%, and diagnosis of opportunistic infections. Once
on ART, children have an initial probability of virologic
suppression, with a corresponding increase in CD4þ% or
CD4þ cell count. Among patients with virologic
suppression, there is a small monthly risk of subsequent
loss of treatment efficacy (‘late failure’). This leads to
virologic rebound, CD4þ% or CD4þ decline after aealth, Inc. All rights reserved.
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until the next available, effective ARTregimen is initiated.
We previously calibrated the model to match survival data
for HIV-infected African children not treated with ART
[12,16]. For this analysis, we also fitted the model to rates
of opportunistic infection (0.7–9.3/100 person-years)
and mortality (3.29/100 person-years) from ART-treated
children in the P1060 trial, as well as published
probabilities of switching from first-line to second-line
ART (9–22% at 36 months; Appendix, http://links.lww.
com/QAD/A686) [8,9].
Modeled population
In the base-case analysis, we modeled South African
children infected during pregnancy/delivery and pre-
senting to care at 12 months of age. Although WHO
guidelines combine first-line ART recommendations for
all children below 3 years of age, mortality and disease
progression differ in infants compared to 2 and 3-year-
olds [16,17]. Because HIV-infected children present to
ART programs in sub-Saharan Africa at a range of ages,
we conducted sensitivity analyses to examine whether age
at presentation to care (6, 24, and 35 months) impacted
the specific comparison between first-line lopinavir/
ritonavir and first-line nevirapine (Table 1) [17,19]. In the
absence of data specific to children infected through
breastfeeding, who may have slower disease progression
than children infected during pregnancy or delivery, we
also examined the impact of wide ranges in opportunistic
infection and mortality rates [16].
Modeled treatment strategies
No ART included routine clinical care, as well as
opportunistic infection prophylaxis and treatment. First-
line nevirapine additionally included nevirapine with
abacavir/lamivudine, followed after observed first-line
failure by second-line lopinavir/ritonavir/zidovudine/
lamivudine. First-line lopinavir/ritonavir included lopi-
navir/ritonavir with abacavir/lamivudine, followed by a
second-line NNRTI (nevirapine if switchingbefore 3 years
of age, or efavirenz if switching after age 3 years) with
zidovudine/lamivudine [10]. ART initiation, monitoring,
and switching followed WHO 2013 Guidelines, with two
additions: ART switching before age 3 years and a 6-month
delay between confirmation of first-line failure and
initiation of second-line ART (Appendix, http://links.
lww.com/QAD/A686) [10,15]. Given limited current
treatment options, modeled children remained on the last
available line of ART lifelong [15,20].
Input data
We used International Epidemiologic Database to
Evaluate AIDS (IeDEA) East African data to derive rates
of CD4þ% or CD4þ decline, opportunistic infections,
and death through age 13 years, and data from the Cape
Town AIDS Cohort to derive event risks at ages greater
than 13 (Appendix, http://links.lww.com/QAD/A686) Copyright © 2015 Wolters Kluwe[21,22]. Base-case ART data were from the P1060 trial,
including 24 and 48-week rates of RNA suppression,
CD4þ% gains on suppressive ART, and risk of late failure
on each regimen (Table 1; Appendix, http://links.lww.
com/QAD/A686) [8,9].
We calculated the costs of HIV-related care by
multiplying the resources used (e.g. outpatient visits,
inpatient days, laboratory testing, and medications) by
country-specific unit costs for South Africa and Coˆte
d’Ivoire, using pediatric-specific data when possible
(Table 1; Appendix, http://links.lww.com/QAD/A686)
[23–27]. ART costs were from Clinton Health Access
Initiative (CHAI) price lists, calculated for each age
from WHO weight-based dosing recommendations
(Appendix, http://links.lww.com/QAD/A686) [6,11,15].
Costs were from the healthcare system perspective in
2012 USD, discounted at 3% per year.
Sensitivity analyses
We first simulated children presenting to care at age 6, 24,
and 35 months. Next, although we lacked clinical and
resource use data to directly simulate children in Coˆte
d’Ivoire, we examined the impact of markedly lower
healthcare costs by using cost data from this country. We
also varied opportunistic infection and mortality rates
(reflecting populations with different disease progression
rates, such as children with postpartum infection [16]),
healthcare costs, ART costs, and the discount rate
(Appendix, http://links.lww.com/QAD/A686).
Univariate sensitivity analyses: antiretroviral therapy
initiation, switching, and sequencing strategies
In sensitivity analyses, we also modeled the still widely used
WHO 2010 ART initiation guidelines: initiation for all
children below 2 years of age, and initiation based on
CD4þ%, CD4þ cell count, or opportunistic infections in
children aged at least 2 years [15]. Modeled monitoring and
switching strategies includedvariousCD4þ andHIV-RNA
testing frequencies; delays to confirming first-line ART
failureandinitiatingsecond-lineART;andclinical,CD4þ%
or CD4þ cell count, and RNA thresholds for switching to
second-line ART (Appendix, http://links.lww.com/
QAD/A686). Modeled ART sequencing strategies
included: one available line of ART, availability of third-
line darunavir/ritonavir based ART, and additional strat-
egies requested by the WHO HIV Guidelines Committee
(Appendix, http://links.lww.com/QAD/A686).
Univariate sensitivity analyses: clinical impact,
virologic outcomes, and costs of antiretroviral therapy
We derived separate RNA suppression rates and CD4þ%
changes on suppressive ART from the PENPACT-1 trial
in Europe, and North and South America [28]. In a
subgroup of children below 3 years old, PENPACT-1
demonstrated nonsignificantly higher virologic suppres-
sion rates with first-line nevirapine than lopinavir/
ritonavir, in contrast to P1060 (Table 1). We also variedr Health, Inc. All rights reserved.
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Table 1. Selected model input parameters (children aged 0–5 years).a
Clinical Inputs Value Sources
CD4þ% at presentation to care, by age [18]
6 months (sensitivity analysis) 25%
12 months (base-case) 22%
24 and 35 months (sensitivity analyses) 19%
ART efficacy: HIV-RNA <400 copies/ml
at 24 weeks on ARTb P1060 PENPACT-1
First-line nevirapine strategy
Nevirapine (in first-line ART) 75% 77%
Lopinavir/ritonavir (in second-line ART) 75% 81%
(sensitivity analysis: 10–80%) Derived from
[8,9,28]
First-line lopinavir/ritonavir strategy
Lopinavir/ritonavir (in first-line ART) 91% 72%
Nevirapine (in second-line ART) 75% 74%
(Sensitivity analysis: 10–80%)
Darunavir-based regimen (sensitivity
analysis)
95% (assumption)
Risk of virologic failure after suppression
(any ART)
0.91% month (Sensitivity analysis: 0.5–3.6%) Derived from
[8,9,28]
Loss to follow-up after ART initiation
(% risk/month)
0.2 (Sensitivity analysis: 0–0.8) [31,32]
Cost Inputsc Cost (2012 USD) Sources
Opportunistic infection care (per event; range by type of OI)
South Africa $310–2490 [24]
Coˆte d’Ivoire $60–420 [25]
Routine care (per month, range by CD4þ%/CD4þ)d
South Africa $25–205 [22,23]
Coˆte d’Ivoire $30–40 [25,26]
Care in the last month of life
South Africa $800 [22,23]
Coˆte d’Ivoire $65 [25,26]
Antiretroviral regimen costs (per month, range by age/weight)e
Lopinavir/ritonavir (liquid: age <3 years (base case) or
<5 years (sensitivity analyses)
$17–27 (Sensitivity
analysis: "1–15x)
[6,11]
Lopinavir/ritonavir (pediatric or adult tablets) $13–29
Nevirapine (pediatric or adult tablets) $3–8
Nevirapine/zidovudine/lamivudine (pediatric tablets,
age <3 years)
$6–8
Abacavir/lamivudine (pediatric or adult tablets) $8–18
Zidovudine/lamivudine (pediatric or adult tablets) $4–9
Efavirenz (pediatric or adult tablets, age 3 years) $3–7
Darunavir/ritonavir-based third-line ART (in sensitivity
analyses only)
$36–92
aThis table includes selected inputs for children entering care at ages 0–35months, which are applied until children reach 59months of age. At age
60months and beyond, separate sets of input data are applied. Complete inputs are shown in Appendix Table A (http://links.lww.com/QAD/A686)
for children aged below and at least 60 months.
bART efficacy: probability of suppressing HIV-RNA to below 400copies/ml by 24 weeks (in base case analysis) or 48 weeks (in sensitivity analysis)
after initiation of ART. Results from the PENPACT-1 trial are from a posthoc subgroup of children limited to those enrolling before 3 years of age and
treated with nevirapine or lopinavir/ritonavir [8,9,28].
cIn sensitivity analyses, all costs were varied from 0.5–2.0 times the costs shown.
dRoutine clinical care costs include CD4þ and viral load monitoring, according to the modeled scenario.
eMonthly ART drug doses were calculated for children ages 0–13 years old based on the WHO weight-based dosing recommendations. Daily
doses were then multiplied by unit drug costs from the May 2012 Clinton Health Access Initiative (CHAI) antiretroviral drug price list to determine
monthly ART costs by age and weight. All children were assumed to receive liquid/syrup drug formulations until age 3 years for lopinavir/ritonavir
(5 years in sensitivity analyses), and until age 6 months for all other medications, for which dispersible tablets are available. After these ages,
children were assumed to transition to pediatric or adult tablet formulations based on weight-based dosing recommendations. Fixed-dose
combinations were assumed to be used where available [11]. In the absence of data on darunavir/r costs for children, we assumed third-line ART
would have costs equal to twice first-line lopinavir/r-based regimen costs.the efficacy of each second-line regimen (10–80%
24-week RNA <400 copies/ml); time required for initial
RNA suppression (24 or 48 weeks, reflecting slower
virologic suppression in children than adults); loss to follow-
up before and after ART initiation (0–0.8%/month); and Copyright © 2015 Wolters Kluwer Hlate failure rates for each regimen (0.5–3.6%/month,
reflecting medication availability, tolerance, and adher-
ence over time) [5,29–32]. Next, we varied opportunistic
infection and mortality rates for patients on ART,
reflecting data from trials and routine care settingsealth, Inc. All rights reserved.
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Finally, in the absence of data about cold chain costs,
we examined 1–15-fold increases in the cost of liquid
lopinavir/ritonavir [35].
Multivariate sensitivity analyses
We next varied the most influential parameters simul-
taneously in multivariate sensitivity analyses. These
included first-line lopinavir/ritonavir efficacy, first-line
nevirapine efficacy, and the cost of both regimens.Results
Base-case results
Impact of any antiretroviral therapy regimen
In the base-case, projected undiscounted life expectancy
for no ARTwas 2.8 years (Table 2). Both first-line ART
regimens markedly increased projected life expectancy
(27.6–28.8 years) compared to no ART. In lifetime
projections for South Africa, total healthcare costs were
lower with no ART (average undiscounted cost: $11 450/
person) than with either ART regimen. Because ART
averts costly opportunistic infections and deaths, care
costs for children without ART exceeded the costs of
providing both care and ART for 12.4 years (149 months;
Fig. 1, open arrow) [36].
Comparison of first-line antiretroviral therapy regimens
The first-line lopinavir/ritonavir strategy led to a longer
projected life expectancy than the first-line nevirapine
strategy (28.8 vs. 27.6 years; Table 2). Although first-line
lopinavir/ritonavir was the most expensive ART strategy
initially ($1400 vs. $1510 at 1 year), it became cost-saving
compared to first-line nevirapine by 8.7 years (104 months;
Fig. 1, closed arrow). Lifetime costs were $41 350/person
with first-line lopinavir/ritonavir and $44 030/person
with first-line nevirapine (Table 2). Cost-savings resulted
primarily from our assumption of lifelong second-line Copyright © 2015 Wolters Kluwe
Table 2. Base-case model results.
ART
strategy
Undiscounted
LE (years)
Discounted
LE (years)
South Africa; children presenting at age 12 months after in-utero/intrapart
No ART 2.83a 2.52
First-line LPV/r 28.79 17.11
First-line NVP 27.61 16.59
Costs are in 2012 USD. Discounting is at 3% per year. ART, antiretroviral th
LPV/r, lopinavir/ritonavir; NVP, nevirapine.
aLife expectancies are mean values projected by the model for a cohort
expectancies, which value life-years in the future to be worth ‘less’ than life-y
bWHO (WHO-CHOICE) recommendations for country-specific gross dom
primarily on cost per quality-adjusted life-year saved or cost per disability-ad
children, we project nonquality-weighted life expectancy, and thus calcul
cDominated: Here, refers to a strategy that is more expensive and less effecti
cost-saving compared to first-line nevirapine in these scenarios. By convent
instead calculate the ICER of first-line lopinavir/ritonavir compared to noART: second-line lopinavir/ritonavir (in the first-line
nevirapine strategy) was more expensive than a second-line
NNRTI (nevirapine or efavirenz, in the first-line
lopinavir/ritonavir strategy), and this difference out-
weighed the lower costs of nevirapine in first-line ART
(Fig. 2). The ICER of first-line lopinavir/ritonavir
compared to no ART was $800/YLS (Table 2). Per
cost-effectiveness analysis convention, we do not report
ICERs for dominated (more expensive and less effective)
strategies [37]. However, it may be of policy interest to note
that, if first-line lopinavir/ritonavir were not available,
first-linenevirapinewouldbevery cost-effective compared
to no ART, with an ICER of $930/YLS.
Univariate sensitivity analyses
First-line lopinavir/ritonavir remained cost-saving com-
pared to first-line nevirapine for all ages at presentation
(6–35 months) and using Coˆte d’Ivoire costs (Table 3),
although the time required for first-line lopinavir/
ritonavir to become cost-saving compared to first-line
nevirapine was much longer with Coˆte d’Ivoire costs than
with South Africa costs (26.4 vs. 8.7 years; Appendix,
http://links.lww.com/QAD/A686). Results were also
robust to variation in most clinical and economic
parameters (Appendix, http://links.lww.com/QAD/
A686). Policy conclusions were, however, sensitive to
three key types of parameters (Table 3, section B).
Reduced availability or duration of second-line
antiretroviral therapy: first-line lopinavir/ritonavir is
very cost-effective, but not cost-saving
The assumption of lifelong second-line ART was a key
factor in the base case results above. When only one line
of ART was available, or when second-line ART was
stopped at virologic failure, first-line lopinavir/ritonavir
remained more effective than first-line nevirapine, but
became more expensive. In these scenarios, first-line
lopinavir/ritonavir was very cost-effective compared to
first-line nevirapine (ICERs: $2190/YLS and $570/
YLS). As in the base-case, however, first-line lopinavir/r Health, Inc. All rights reserved.
Undiscounted
lifetime costs
Discounted
lifetime costs
ICER
($/life-year saved)
um infection
11450 10290
41350 21950 800b
44030 23370 Dominatedc
erapy; ICER, incremental cost-effectiveness ratio; LE, life expectancy;
of children presenting to care at 12 months of age. Discounted life
ears in the present, are not directly comparable to clinical experience.
estic product (GDP)-based cost-effectiveness thresholds are based
justed life-year averted. Because of limited health utility weight data in
ate ICERs in dollars per life-year saved.
ve than its alternative. This indicates that first-line lopinavir/ritonavir is
ion, we do not calculate an ICER comparing these two strategies, and
ART.
1252 AIDS 2015, Vol 29 No 10
0
2000
4000
6000
8000
10 000
12 000
14 000
16 000
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 12 24 36 48 60 72 84 96 108 120 132 144 156 168 180 192 204 216 228 240
Per-person cum
ulative costs ($)
Pr
op
or
tio
n 
al
ive
Months since presentation to care
Survival
NoART
1st line NVP
1st line LPV/r
Cost
NoART
1st line NVP
1st line LPV/r
Fig. 1. Projected survival and costs with alternative first-line pediatric antiretroviral therapy regimens. Results are shown for
the base case analysis: South African children presenting to care at 12 months of age. The proportion of patients alive is on the
left-hand vertical axis (blue lines) and the per-person cumulative costs are on the right-hand vertical axis (black lines). Survival
and per-person undiscounted costs are projected over 20 years (240 months) since presentation to care, shown on the
horizontal axis. The no ART strategy is represented by solid lines, first-line NVP by dashed lines, and first-line LPV/r by dotted
lines. The solid arrow refers to the time after presentation when first-line LPV/r becomes cost-saving compared to first-line NVP:
104 months (8.7 years). Of note, both ART strategies are cost-saving compared to no ART until 149 months (12.4 years) after
presentation (open arrow), due to the high costs of care for opportunistic infections and death compared to medication costs.
ART, antiretroviral therapy; LPV/r, lopinavir/ritonavir; NVP, nevirapine.ritonavir remained cost-saving in South Africa when
switching from first-line to second-line ARTwas delayed
(e.g. if HIV-RNA or CD4þ monitoring was unavailable,
or if CD4þ confirmation of clinical or virologic failure
was required) and when the costs of the last available line
of ART were equalized by a darunavir/ritonavir-based
third-line regimen in both strategies (Appendix, http://
links.lww.com/QAD/A686).
Virologic outcomes of first-line and second-line
antiretroviral therapy: first-line nevirapine is very cost-
effective
When the efficacies of the first-line ART regimens were
reversed using PENPACT-1 trial data (Table 1), first-line
nevirapine became the more effective and more
expensive strategy, and was very cost-effective compared
to no ART (ICER: $810/YLS) [28]. If first-line
lopinavir/ritonavir and first-line nevirapine efficacies
were held constant (using P1060 data, as in the base-case),
but the efficacy of a second-line NNRTI following first-
line lopinavir/ritonavir was very low (40% RNA
suppression at 24 weeks), first-line nevirapine was also
more effective, more expensive, and very cost-effective Copyright © 2015 Wolters Kluwer H(ICER: $1110/YLS at 40% suppression) compared to
first-line lopinavir/ritonavir.
Tolerability and cost of liquid lopinavir/ritonavir: first-
line nevirapine is very cost-effective
When the risk of late virologic failure for lopinavir/
ritonavir in first-line ART was increased 2.1-fold to
1.9%/month (e.g. as might occur with poor tolerability or
medication stock-outs of lopinavir/ritonavir syrup), first-
line nevirapine was more effective and very cost-effective
compared to first-line lopinavir/ritonavir (ICER: $6310/
YLS). When the cost of liquid lopinavir/ritonavir was
increased 4.5-fold from the base-case (e.g. reflecting costs
for establishing and maintaining cold chains), there was
no change in projected life expectancies, but first-line
lopinavir/ritonavir was no longer cost-saving. At least
15-fold increases in liquid lopinavir/ritonavir costs, first-
line lopinavir/ritonavir was no longer very cost-effective.
Multivariate sensitivity analyses
Results of simultaneous variation in first-line ART
efficacy and the costs of lopinavir/ritonavir and
nevirapine are shown in Fig. 3. When the efficacyealth, Inc. All rights reserved.
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Fig. 2. Duration on each modeled antiretroviral therapy regimen and impact on total lifetime healthcare costs.Months spent
on NVP-based ART (light gray bars), LPV/r-based ART (dark gray bars), and DRV/r-based ART (black bars) are shown, in
undiscounted months, for base case and key sensitivity analyses described in the text. Total per-person, undiscounted lifetime
costs are shown at the right of the bars for each treatment strategy. Results shown here are for children presenting to care at
12 months of age in South Africa; findings for children presenting at other ages and using healthcare costs from Coˆte d’Ivoire
followed similar trends. ART, antiretroviral therapy; DRV/r, darunavir boosted with ritonavir; LPV/r, lopinavir/ritonavir; NVP,
nevirapine; VL, viral load.(proportion of treated children with HIV-RNA
<400 copies/ml at 24 weeks) of one first-line regimen
is greater than the efficacy of the other, GDP-based
interpretation of cost-effectiveness generally supports the
choice of the more effective first-line regimen (panel A).
Because lopinavir/ritonavir and nevirapine are used in
both strategies (as either first-line or second-line ART),
variations in drug costs exert only a modest impact on the
economically preferred strategy (panels B and C).Discussion
We used data from the IMPAACT P1060 trial and other
sources to estimate the cost-effectiveness of first-line ART
for children below 3 years of age in sub-Saharan Africa.
There were four key findings from this study. First, treating
HIV-infected children with any ARTregimen dramatically
increased survival; ARTalso saved money in the short term
by averting opportunistic infections, as has previously been
reported in South Africa [36]. Compared to no ART, both
regimens were very cost-effective in the long term (ICER
of first-line lopinavir/ritonavir compared to no ART:
$800/YLS; if first-line lopinavir/ritonavir was not
available, ICER of first-line nevirapine compared to no Copyright © 2015 Wolters KluweART: $930/YLS). In addition, projected life expectancies
were longer for children presenting to care at older
compared to younger ages (Table 3). This result reflects
very high morbidity and mortality among young infants
who do not access care or ART [16,19,38]. Because
children who do not survive to access ART were by
definition excluded from these analyses, our results are not
intended to compare the relative value of ART initiation at
older versus younger ages. Increasing access to early
pediatric HIV diagnosis and to pediatric ART is therefore
critical, regardless of the ART regimen chosen.
Second, first-line lopinavir/ritonavir was cost-saving
compared to first-line nevirapine over children’s lifetimes.
This results both from the greater lopinavir/ritonavir
efficacy reported in P1060, averting more care costs for
morbidity and mortality in the first few years after ART
initiation than nevirapine, and from the assumption of
lifelong second-line ART (Fig. 2) [10,15]. Importantly,
these cost-savings occurred well beyond the horizons of
clinical trials: more than 8 years after ART initiation in
South Africa, and more than 26 years after ART initiation
with lower healthcare costs from Coˆte d’Ivoire. In the
much nearer future, however, the availability and costs of
second-line and third-line pediatric ART will likely
change, as will ART monitoring and switching protocols.r Health, Inc. All rights reserved.
 Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
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Table 3. Sensitivity analysis results.
ART strategy (ordered by costs)a Undiscounted LE (years) Discounted LE (years) Discounted lifetime costs ICER ($/life-years saved)
Alternative patient populations and healthcare costs
South Africa: in-utero/intrapartum infection; presenting age 6 months
No ART 2.50 2.23 8520
First-line LPV/r 27.45 16.31 20620 860
First-line NVP 26.29 15.81 21960 Dominatedb
South Africa: in-utero/intrapartum infection; presenting age 24 monthsc
No ART 3.54 3.09 12670
First-line LPV/r 28.71 17.10 27220 710
First-line NVP 27.52 16.59 29600 Dominated
South Africa: in-utero/intrapartum infection; presenting age 35 monthsc
No ART 4.71 4.03 14420
First-line LPV/r 29.46 17.60 23240 650
First-line NVP 28.36 17.11 24790 Dominated
Coˆte d’Ivoire: in-utero/intrapartum infection; presenting age 12 monthsd
No ART 2.83 2.52 1820
First-line LPV/r 28.79 17.11 15120 910
First-line NVP 27.62 16.58 15480 Dominated
Additional sensitivity analyses (South Africa, in-utero/intrapartum infection; presenting age 12 months)
One line of ART available
No ART 2.83 2.52 10290
First-line NVPa 22.42 14.57 24890 1210
First-line LPV/r 23.84 15.31 26490 2190
Stop second-line ART at failure
No ART 2.83 2.52 10290
First-line NVPa 23.76 15.03 17360 565
First-line LPV/r 25.18 15.74 17760 570
PENPACT-1 ART efficacies
No ART 2.83 2.52 10290
First-line LPV/r 29.28 16.96 22240 Weakly dominatede
First-line NVP 30.42 17.39 22370 810
Second-line NNRTI efficacy (40%)
No ART 2.83 2.52 10290
First-line LPV/r 26.51 16.26 23010 930
First-line NVP 27.61 16.59 23370 1110
2.1 late failure for first-line LPV/r (1.9%/month)f
No ART 2.83 2.52 10290
First-line LPV/r 26.60 16.38 22070 850
First-line NVP 27.61 16.59 23370 6310
4.5 cost of liquid LPV/r ($80–105 per month for children <3 years of age)
No ART 2.83 2.52 10290
First-line NVPa 28.77 16.59 23480 Weakly dominated
First-line LPV/r 27.58 17.10 23510 910
15.0 cost of liquid LPV/r ($260–330 per month for children <3 years of age)
No ART 2.83 2.52 10290
First-line NVPa 27.58 16.58 23780 960
First-line LPV/r 28.79 17.09 28170 8640
Liquid LPV/r used until age 5
No ART 2.83 2.52 10290
First-line LPV/r 28.77 17.09 22730 850
First-line NVP 27.59 16.60 23440 Dominated
Costs are in 2012 USD. Discounting is at 3% per year (results using alternative discount rates are shown in the Appendix (http://links.lww.com/
QAD/A686). ART, antiretroviral therapy; DRV/r, darunavir/ritonavir; ICER, incremental cost-effectiveness ratio; LE, life expectancy; LPV/r,
lopinavir/ritonavir; NNRTI, nonnucleoside reverse transcriptase inhibitor; NVP, nevirapine.
aStrategies are listed in order of increasing costs. As a result, the order of the three treatment strategies changes between scenarios. Scenarios in
which first-line NVP is less expensive over a lifetime horizon than first-line LPV/r are highlighted with footnote (a).
b‘Dominated’ in this table refers to strong dominance: a strategy is both more expensive and less effective than its next less expensive alternative.
cIn these analyses, the model simulates a cohort of children presenting to care and initiating ART at ages 6, 12, 24, and 35 months. Morbidity and
mortality occurring among children before these ages are not included in these analyses. As a result, children presenting to care at older ages have
longer projected life expectancies both with and without ART. This occurs because the model incorporates age-stratified mortality risks from HIV
and non-HIV causes. High mortality rates among young, untreated children mean that children who survive without treatment to present to care at
older ages are generally less sick, reflecting the ‘survivor bias’ seen in most cohorts of HIV-infected children [16–18]. These analyses are intended
to evaluate the impact of age at ART initiation on the comparison between the two first-line regimens, and not to compare the outcomes of early
versus delayed ART initiation.
dBase-case results using Coˆte d’Ivoire costs are shown here. Full results for all analyses using Coˆte d’Ivoire costs are in the Appendix (http://
links.lww.com/QAD/A686).
eWeakly dominated.Here, refers to extended dominance: the incremental cost-effectiveness ratio (ICER) of the nondominated strategy compared to
the dominated strategy is less than the ICER of the dominated strategy compared to no ART, indicating that the dominated strategy is an inefficient
use of healthcare resources.
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First-line LPV/r preferred
     Cost-saving
     Very cost-effective
First-line NVP preferred
     Very cost-effective
     Dominant (see legend)
Fig. 3. Multivariate sensitivity analyses: impact of simultaneous variation in antiretroviral therapy efficacy and costs. In each
panel, the efficacy (proportion of treated children with HIV-RNA <400 copies/ml at 24 weeks) of the first-line LPV/r regimen is
shown on the horizontal axis, and the efficacy of the first-line NVP regimen is shown on the vertical axis. Panel a shows results at
base-case ART costs. Panel b shows results when the cost of LPV/r is reduced by half (when used in first-line or second-line ART, at
any age). Panel c shows results when the cost of NVP is reduced by half (again, when used in first-line or second-line ART, at any
age). Costs and life-years are discounted at 3% per year. Green shading indicates scenarios in which the first-line LPV/r strategy is
cost-saving (leading to greater life expectancy and lower lifetime costs), compared to the first-line NVP strategy. Yellow shading
indicates scenarios in which first-line LPV/r is very cost-effective compared to first-line NVP (ICER of first-line LPV/r compared to
first-line NVP is less than South Africa per-capita GDP ($7500)/YLS, or first-line NVP is more effective and more expensive, but its
ICER compared to first-line LPV/r is greater than $7500/YLS). Orange shading indicates scenarios in which first-line LPV/r is no
longer very cost-effective (first-line LPV/r is more effective and more expensive than first-line NVP, but its ICER relative to first-line
NVP is>$7500/YLS, or first-line NVP is more effective andmore expensive, and its ICER relative to first-line LPV/r is<$7500). Red
shading indicates scenarios in which first-line LPV/r is strongly or weakly dominated by first-line NVP (weak dominance: first-line
LPV/r is less effective and less expensive, but represents an inefficient use of resources; strong dominance: first-line LPV/r leads to
lower life expectancy and greater lifetime costs). Following WHO GDP-based guidance, cost-effectiveness results support the
choice of first-line LPV/r in the green- and yellow-shaded scenarios and the choice of first-line NVP in the orange- and red-shaded
scenarios. ART, antiretroviral therapy; GDP: gross domestic product; ICER, incremental cost-effectiveness ratio; LPV/r, lopinavir/
ritonavir; NVP, nevirapine; YLS, year of life saved.If the relative duration and cost of first-line compared to
second-line ARTare altered, first-line lopinavir/ritonavir
may no longer be cost-saving. First-line lopinavir/
ritonavir remained more effective than first-line Copyright © 2015 Wolters Kluwenevirapine, and very cost-effective, in many of the
scenarios that we evaluated, however, suggesting that it
will likely remain of good value as second-line and third-
line ART practices evolve.r Health, Inc. All rights reserved.
1256 AIDS 2015, Vol 29 No 10Third, cost-effectiveness results depended on the relative
efficacy of lopinavir/ritonavir and nevirapine in both
first-line and second-line ART. The importance of first-
line efficacy was demonstrated by PENPACT-1 trial data.
If first-line nevirapine has higher rates of virologic
suppression than lopinavir/ritonavir, as in the PEN-
PACT-1 subgroup of children below 3 years old, then the
first-line nevirapine strategy will be more effective and
cost-effective in some settings. The nonsignificant super-
iority of nevirapine in PENPACT-1 was based on a small
post-hoc subgroup analysis; the primaryoutcome of 4-year
change in HIV-RNA was not different between children
randomized to protease inhibitor versus NNRTI-based
ART [28].
The importance of second-line ART efficacy was
highlighted in sensitivity analyses which varied this
parameter. The first-line nevirapine/second-line lopina-
vir/ritonavir sequence is widely used, with excellent
second-line lopinavir/ritonavir outcomes in children and
adults [29,39,40]. The first-line lopinavir/ritonavir/
second-line NNRTI sequence is infrequently described.
Sparse observational data suggest 24–48-week suppres-
sion rates of 16–45% in children and adults on second-
line nevirapine or efavirenz [29,40–42]. These low rates
may reflect poor adherence, or may result from
accumulation of resistance to nucleoside reverse tran-
scriptase inhibitors (zidovudine, lamivudine, and abaca-
vir) on failing protease inhibitor-based ART, causing the
NNRTI used with these drugs in second-line ART to act
essentially as monotherapy. This was likely a greater
concern with older protease inhibitor regimens (e.g. full-
dose ritonavir) [42]. In contrast, PENPACT-1 and the
South African Children with HIV Early Antiretroviral
(CHER) trial reported few resistance mutations even
when children remained on failed protease inhibitor-
based ART, and both PENPACT-1 and P1060 observed
second-line NNRTI suppression rates greater than 70%,
although in small numbers of children [8,9,28,43]. We
found that the efficacy of second-line NNRTI-based
ART needed to be very low (40% RNA suppression at
24 weeks) to render the first-line lopinavir/ritonavir
strategy no longer more effective or very cost-effective.
Fourth, lopinavir/ritonavir for young children is for-
mulated as a syrup, which requires refrigeration and,
although well tolerated in P1060, may cause adverse
gastrointestinal effects [5,8,9]. Although we lacked data on
the cost of establishing and maintaining cold chains, we
found that these would need to increase the total cost of
liquid lopinavir/ritonavir more than 4.5-fold to render the
first-line lopinavir/ritonavir strategy no longer cost-saving.
Cold chains may, however, be infeasible in some settings
with severely constrained human resources and healthcare
infrastructure, regardless of cost [35]. We also examined the
impact of increased risks of virologic failure after the first
6 months of first-line lopinavir/ritonavir, such as might
occur if lopinavir/ritonavir syrup is difficult for young Copyright © 2015 Wolters Kluwer Hchildren to tolerate, and thus leads to low adherence over
time, or if medication stock-outs lead to development of
drug-resistant HIV [7]. We found that this late failure risk
would need to increase by only 2.1-fold, from 0.9 to 1.9%/
month, to change policy conclusions. Novel formulations,
such as the heat-stable lopinavir/ritonavir sprinkles that
may soon be US Food and Drug Administration (FDA)-
approved [44,45], or a strategyof switching tonevirapineor
efavirenz after suppression on lopinavir/ritonavir, may
reduce the costs and improve the tolerability of a first-line
lopinavir/ritonavir regimen for children too young to
swallow pills [30,46].
The present study has several limitations related to model-
based cost-effectiveness analyses. Model-based analyses
necessarily extrapolate long-term outcomes from short-
term data. Because pediatric ARTwas introduced less than
10 years ago in most African programs, long-term
outcomes for children on currently used ART regimens
in Africa are not yet available. We therefore calibrated our
model to fit short-term opportunistic infection and
mortality observations for ART-treated children
(Appendix, http://links.lww.com/QAD/A686) [8,9].
This led to projected life expectancies (27–28 years)
comparable to estimates for young South African adults,
but necessarily longer than the current experience of
clinicians caring for HIV-infected children [47]. We
examined this uncertainty through a range of scenarios
leading to shorter and longer life expectancies, and the
clinical and economic value of first-line lopinavir/ritonavir
remained unchanged. In addition, GDP-based cost-
effectiveness thresholds raise important concerns about
generalizability and equity across countries, and do not
address possible changes in country GDPs over time [48].
Although an alternative approach has not been widely
accepted, comparing results to published ICERs for
common HIV therapies ($500–5000/YLS), rather than to
GDP thresholds, did not change policy conclusions [49].
Finally, by convention, cost-effectiveness analysis considers
long-term (lifetime) horizons [37]. Cost-effectiveness is
not the same as affordability, however, and is onlyone of the
many critical factors in decision-making. We also present
detailed survival and cost estimates for each year of our
simulation (Fig. 2; Appendix Fig. A, http://links.lww.
com/QAD/A686). Given limited current ART avail-
ability, providing nevirapine-based ART to greater
numbers of children, even if it may be slightly less effective
in the short term and more expensive in the long term, may
be preferred by some decision-makers.
Additional limitations relate to trial strategies and data
availability. We simulated the regimens in the P1060 trial;
following the trial protocol, we did not model co-
administration with tuberculosis therapy. If efavirenz or
other medications that can be co-administered with
tuberculosis therapy become widely used for children
below 3 years old, the benefit of first-line lopinavir/
ritonavir may change [50]. Although we modeledealth, Inc. All rights reserved.
Cost-effective first-line antiretroviral therapy Ciaranello et al. 1257children infected during pregnancy or delivery, sensitivity
analyses reflecting lower risks of opportunistic infections
and mortality suggest that conclusions would be similar
for postnatally HIV-infected children [16]. Finally, we did
not have detailed data for children in Coˆte d’Ivoire; we
used clinical data from East and Southern Africa and
varied only costs. Although our approach to deriving
healthcare costs matched published economic data from
South Africa and Zambia (a low-income country with
GDP similar to Coˆte d’Ivoire), such an approach
excluded country-specific factors, such as reduced
malaria risk with protease inhibitors, which might change
the clinical and cost-effectiveness of first-line lopinavir/
ritonavir [36,51,52].
In conclusion, we find that treating HIV-infected children
with any ART regimen dramatically increases life
expectancy, is cost-saving in the short term, and is very
cost-effective in the long term, compared to no ART. On
the basis of data from theP1060 trialwith the assumption of
lifelong, currently available second-line ART, a first-line
regimen including lopinavir/ritonavir will improve out-
comes and save money compared to a first-line regimen
including nevirapine. These findings support the adoption
of WHO 2013 HIV treatment guidelines in most settings
in which lopinavir/ritonavir is feasible. Increasing the
availability of pediatric ART is critical and will be of
excellent value, regardless of the initial regimen used.Acknowledgements
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